Search

Your search keyword '"Ly QP"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Ly QP" Remove constraint Author: "Ly QP"
43 results on '"Ly QP"'

Search Results

1. Single-cell RNA-sequencing of human spleens reveals an IDO-1 + tolerogenic dendritic cell subset in pancreatic cancer patients that is absent in normal individuals.

2. MUC16 Retention after Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma.

Catalog

Books, media, physical & digital resources

3. Mucins as contrast agent targets for fluorescence-guided surgery of pancreatic cancer.

4. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

5. Metastatic Giant Cell Tumor Causing Small Bowel Intussusception on 18 F-FDG PET/CT.

6. Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer.

7. Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.

8. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.

9. Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1-CD44 Axis.

11. Repurposing Niclosamide for Targeting Pancreatic Cancer by Inhibiting Hh/Gli Non-Canonical Axis of Gsk3β.

12. Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis.

13. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis.

14. Comparative phenotypes of peripheral blood and spleen cells from cancer patients.

15. Development of a MUC16-Targeted Near-Infrared Fluorescent Antibody Conjugate for Intraoperative Imaging of Pancreatic Cancer.

16. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.

17. Tuned near infrared fluorescent hyaluronic acid conjugates for delivery to pancreatic cancer for intraoperative imaging.

18. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.

19. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy.

20. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

21. Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association.

22. Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation.

23. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.

24. Indocyanine green loaded hyaluronan-derived nanoparticles for fluorescence-enhanced surgical imaging of pancreatic cancer.

25. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

26. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.

27. Duodenal gangliocytic paraganglioma with lymph node metastases: A case report and comparative review of 31 cases.

28. Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.

29. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.

30. Clinical presentation and outcome of nonfunctional pancreatic neuroendocrine tumors in a modern cohort.

31. A preoperative nomogram to predict the risk of perioperative mortality following gastric resections for malignancy.

32. Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.

33. Pre-operative nomogram to predict risk of peri-operative mortality following liver resections for malignancy.

34. Gene expression profiling of colorectal mucinous adenocarcinomas.

35. Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up.

37. Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review.

38. Modern surgical considerations for gastric cancer.

39. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer.

40. Evidence that the V832M E-cadherin germ-line missense mutation does not influence the affinity of alpha -catenin for the cadherin/catenin complex.

41. Clinical relevance of targeted interference with Src-mediated signal transduction events.

42. Thrombospondin-1 promotes proliferative healing through stabilization of PDGF.

43. Nonviable Staphylococcus aureus and its peptidoglycan stimulate macrophage recruitment, angiogenesis, fibroplasia, and collagen accumulation in wounded rats.